Close Menu

KRAS Biomarkers

News and reporting on KRAS biomarkers.

Phase I data at ESMO suggested that the experimental drug may be particularly effective in KRAS G12C-mutated lung and colon cancers.

Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.

The partners are hoping to leverage their expertise to advance drugs with a novel mechanism of action that will target a broader range of RAS mutations.

Qualigen Therapeutics will acquire intellectual property rights to the family of RAS-targeting small molecules and pay royalties to Louisville upon commercialization.

The study will evaluate the safety, tolerability and clinical activity of JSI-1187 in patients with relapsed, refractory solid tumors containing mutations in the MAPK pathway.

The company will study its investigational drug rigosertib in combination with Opdivo in patients with KRAS-mutated lung cancer.

The Amgen-sponsored Phase Ib study is evaluating the combination in patients with advanced solid tumors characterized by KRAS G12C mutations.

Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.

Oncolytics will run two biomarker validation studies before pursuing the first registration enabling trial in HR-positive, HER2-negative breast cancer for Reolysin.

In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.

Pages